SV Biotech Crossover
QuietLondon, X0Last fund filed December 2021Biotechnology
- Funds on file
- 1
London, X0Last fund filed December 2021Biotechnology
0 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| SV Biotech Crossover Opportunities Fund LP | December 2021 | $350.0M | $135.2M | 7 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. Form D carries no per-investor amount, so a firm’s own cheque is not recoverable here.
3 partners are named across this firm’s filings, 0 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats, 24mo |
|---|---|---|---|
| Houman AshrafianOn the current fund | Quiet | None listed | 0 |
| Kate BinghamOn the current fund | Quiet | None listed | 0 |
| Nicola TrbovicOn the current fund | Quiet | None listed | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. On a firm it is the total across its partners, so an active firm may be four partners taking one seat each rather than one person moving fast. It undercounts partners who invest without taking a board seat, and Form D lags a closing by weeks — so Quiet means the paperwork is quiet, not the person.